Payers Want Access To US FDA's Pre-Submission Meetings
As sponsors push for more access to physicians, payers hope to be able to gather more pre-approval information about drugs – like they now can with devices – for budgeting and patient access.
You may also be interested in...
US Academy of Managed Care Pharmacy is developing language to protect exchange of clinical and economic information on pipeline products between manufacturers and healthcare decision-makers; safe harbor could find a home in legislation reauthorizing FDA user fee programs.
Pfizer CEO Ian Read, Regeneron CEO Leonard Schleifer, Gilead CEO John Milligan and Lilly’s incoming CEO David Ricks discussed pharma’s reputation problem during the Forbes Healthcare Summit.
Seeking relaxation of US agency restrictions, Pfizer cites three examples where company delayed or decided against distributing medically relevant information beyond the product labeling; PhRMA survey shows almost half of all requests for information by prescribers and payers relate to off-label use.